NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependence and addiction, announces that its clinical study intended to evaluate the complementarity of its NFL-101 treatment as a smoking cessation therapy with other smoking cessation treatments and in particular nicotine substitutes, was approved by the National Agency for the Safety of Medicines and Health Products (ANSM), and received the favorable opinion of the Committee for the Protection of Persons (CPP).
NFL Biosciences will implement a Phase IIa clinical study, entitled PRECESTO, the main objective of which is to validate the complementarity of NFL-101 with other smoking cessation treatments and in particular nicotine substitutes (transdermal patches (patches), tablets , chewing gum, inhalers and nicotine spray) for the development of an innovative treatment method combining NFL-101 and other smoking cessation methods.
